Allecra Therapeutics’ Licensing Agreement with Advanz Pharma

Baker McKenzie advised Allecra Therapeutics on the deal.

Allecra Therapeutics signed an exclusive licensing agreement with Advanz Pharma Corp. Limited, a specialty pharmaceutical company with a strategic focus on hospital medicines in Europe.

Under the terms of the agreement, Advanz Pharma gains the rights to develop and commercialize Allecra’s antibiotic drug candidate cefepime/enmetazobactam within the European Union, the United Kingdom, Switzerland, and Norway.

The Baker Mckenzie team was led by partner Julia Braun (Picture), Transactional IP: Dr. Julia Schieber (senior associate, Zurich), Sylvia Polydor (associate, Zurich), Corporate/M&A: Dr. Julia Rossié, Michelle Karrer (both associates, Munich), Foreign Trade Law: Anahita Thoms (partner, Berlin), Alexander Ehrle (associate, Berlin), Antitrust: Dr. Christian Burholt (partner, Berlin), Ann-Kristin Freiheit (associate, Frankfurt).

Involved fees earner: Julia Braun – Baker McKenzie; Christian Burholt – Baker McKenzie; Alexander Ehrle – Baker McKenzie; Ann-Kristin Freiheit – Baker McKenzie; Michelle Karrer – Baker McKenzie; Sylvia Polydor – Baker McKenzie; Julia Rossié – Baker McKenzie; Julia Schieber – Baker McKenzie; Anahita Thoms – Baker McKenzie;

Law Firms: Baker McKenzie;

Clients: Allecra Therapeutics ;